Intrinsic value of CryoPort - CYRX

Previous Close

$15.97

  Intrinsic Value

$7.76

stock screener

  Rating & Target

str. sell

-51%

Previous close

$15.97

 
Intrinsic value

$7.76

 
Up/down potential

-51%

 
Rating

str. sell

We calculate the intrinsic value of CYRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.00
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  6
  19
  30
  44
  64
  91
  125
  168
  220
  283
  358
  444
  543
  654
  779
  916
  1,065
  1,227
  1,401
  1,586
  1,784
  1,992
  2,211
  2,442
  2,683
  2,935
  3,197
  3,471
  3,755
  4,051
  4,359
Variable operating expenses, $m
 
  16
  25
  37
  54
  76
  104
  140
  184
  237
  299
  372
  454
  548
  652
  766
  891
  1,027
  1,172
  1,328
  1,493
  1,667
  1,851
  2,044
  2,246
  2,456
  2,676
  2,905
  3,143
  3,391
  3,648
Fixed operating expenses, $m
 
  10
  10
  11
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  14
  14
  14
  14
  15
  15
  15
  16
  16
  16
  17
  17
  18
  18
  18
  19
  19
Total operating expenses, $m
  12
  26
  35
  48
  65
  87
  115
  152
  196
  249
  311
  385
  467
  561
  666
  780
  905
  1,041
  1,187
  1,343
  1,508
  1,683
  1,867
  2,060
  2,263
  2,473
  2,694
  2,923
  3,161
  3,410
  3,667
Operating income, $m
  -6
  -7
  -6
  -3
  0
  4
  9
  16
  24
  34
  46
  60
  76
  93
  113
  135
  159
  185
  214
  243
  275
  309
  344
  382
  420
  461
  504
  548
  594
  642
  691
EBITDA, $m
  -6
  -7
  -5
  -3
  1
  5
  11
  18
  28
  39
  52
  67
  84
  104
  126
  150
  177
  206
  236
  269
  305
  342
  381
  422
  464
  509
  556
  605
  655
  708
  763
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  1
  2
  2
  3
  4
  5
  6
  7
  8
  10
  11
  13
  15
  17
  19
  21
  24
  26
  29
  31
  34
  37
  40
  43
Earnings before tax, $m
  -10
  -7
  -6
  -4
  -1
  3
  8
  14
  22
  32
  43
  56
  71
  88
  106
  127
  150
  174
  200
  229
  258
  290
  323
  358
  394
  432
  472
  513
  557
  601
  648
Tax expense, $m
  0
  0
  0
  0
  0
  1
  2
  4
  6
  9
  12
  15
  19
  24
  29
  34
  40
  47
  54
  62
  70
  78
  87
  97
  106
  117
  127
  139
  150
  162
  175
Net income, $m
  -10
  -7
  -6
  -4
  -1
  2
  6
  11
  16
  23
  31
  41
  52
  64
  78
  93
  109
  127
  146
  167
  189
  212
  236
  261
  288
  316
  345
  375
  406
  439
  473

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  5
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  8
  11
  17
  26
  38
  54
  74
  99
  130
  167
  211
  262
  320
  386
  459
  540
  628
  723
  825
  935
  1,051
  1,174
  1,303
  1,439
  1,581
  1,729
  1,884
  2,045
  2,213
  2,387
  2,569
Adjusted assets (=assets-cash), $m
  3
  11
  17
  26
  38
  54
  74
  99
  130
  167
  211
  262
  320
  386
  459
  540
  628
  723
  825
  935
  1,051
  1,174
  1,303
  1,439
  1,581
  1,729
  1,884
  2,045
  2,213
  2,387
  2,569
Revenue / Adjusted assets
  2.000
  1.727
  1.765
  1.692
  1.684
  1.685
  1.689
  1.697
  1.692
  1.695
  1.697
  1.695
  1.697
  1.694
  1.697
  1.696
  1.696
  1.697
  1.698
  1.696
  1.697
  1.697
  1.697
  1.697
  1.697
  1.698
  1.697
  1.697
  1.697
  1.697
  1.697
Average production assets, $m
  0
  3
  5
  7
  11
  15
  20
  27
  36
  46
  59
  73
  89
  107
  128
  150
  175
  201
  230
  260
  293
  327
  363
  400
  440
  481
  524
  569
  616
  664
  715
Working capital, $m
  4
  -2
  -3
  -4
  -6
  -9
  -12
  -16
  -21
  -27
  -34
  -43
  -52
  -63
  -75
  -88
  -102
  -118
  -134
  -152
  -171
  -191
  -212
  -234
  -258
  -282
  -307
  -333
  -361
  -389
  -418
Total debt, $m
  1
  2
  4
  7
  11
  16
  23
  31
  42
  54
  69
  86
  106
  128
  153
  180
  210
  242
  277
  314
  353
  394
  438
  484
  532
  582
  635
  689
  746
  805
  866
Total liabilities, $m
  2
  4
  6
  9
  13
  18
  25
  33
  44
  56
  71
  88
  108
  130
  155
  182
  212
  244
  279
  316
  355
  397
  440
  486
  534
  585
  637
  691
  748
  807
  868
Total equity, $m
  6
  7
  12
  17
  25
  35
  49
  65
  86
  110
  140
  173
  212
  255
  304
  357
  415
  479
  546
  619
  696
  777
  863
  953
  1,047
  1,145
  1,247
  1,354
  1,465
  1,580
  1,700
Total liabilities and equity, $m
  8
  11
  18
  26
  38
  53
  74
  98
  130
  166
  211
  261
  320
  385
  459
  539
  627
  723
  825
  935
  1,051
  1,174
  1,303
  1,439
  1,581
  1,730
  1,884
  2,045
  2,213
  2,387
  2,568
Debt-to-equity ratio
  0.167
  0.210
  0.310
  0.380
  0.420
  0.450
  0.460
  0.480
  0.480
  0.490
  0.490
  0.500
  0.500
  0.500
  0.500
  0.500
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
  0.510
Adjusted equity ratio
  0.333
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662
  0.662

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -10
  -7
  -6
  -4
  -1
  2
  6
  11
  16
  23
  31
  41
  52
  64
  78
  93
  109
  127
  146
  167
  189
  212
  236
  261
  288
  316
  345
  375
  406
  439
  473
Depreciation, amort., depletion, $m
  0
  0
  0
  1
  1
  1
  2
  3
  4
  5
  6
  7
  9
  11
  13
  15
  17
  20
  23
  26
  29
  33
  36
  40
  44
  48
  52
  57
  62
  66
  71
Funds from operations, $m
  -4
  -7
  -5
  -3
  0
  4
  8
  13
  20
  28
  37
  48
  61
  75
  90
  108
  127
  147
  169
  193
  218
  244
  272
  301
  332
  364
  397
  432
  468
  505
  544
Change in working capital, $m
  0
  -1
  -1
  -1
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -11
  -12
  -13
  -14
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -30
Cash from operations, $m
  -4
  -6
  -4
  -2
  2
  6
  11
  17
  25
  34
  44
  56
  70
  85
  102
  121
  141
  163
  186
  211
  237
  264
  293
  323
  355
  388
  422
  458
  495
  534
  574
Maintenance CAPEX, $m
  0
  0
  0
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -6
  -7
  -9
  -11
  -13
  -15
  -17
  -20
  -23
  -26
  -29
  -33
  -36
  -40
  -44
  -48
  -52
  -57
  -62
  -66
New CAPEX, $m
  -1
  -1
  -2
  -2
  -3
  -4
  -6
  -7
  -9
  -10
  -12
  -14
  -16
  -18
  -20
  -22
  -25
  -27
  -29
  -30
  -32
  -34
  -36
  -38
  -40
  -41
  -43
  -45
  -47
  -49
  -50
Cash from investing activities, $m
  -1
  -1
  -2
  -2
  -4
  -5
  -7
  -9
  -12
  -14
  -17
  -20
  -23
  -27
  -31
  -35
  -40
  -44
  -49
  -53
  -58
  -63
  -69
  -74
  -80
  -85
  -91
  -97
  -104
  -111
  -116
Free cash flow, $m
  -5
  -7
  -6
  -4
  -2
  1
  4
  8
  14
  20
  28
  36
  47
  58
  71
  86
  102
  119
  137
  157
  178
  201
  224
  249
  275
  303
  331
  361
  392
  424
  457
Issuance/(repayment) of debt, $m
  0
  2
  2
  3
  4
  5
  7
  9
  10
  13
  15
  17
  20
  22
  25
  27
  30
  32
  35
  37
  39
  42
  44
  46
  48
  50
  52
  54
  57
  59
  61
Issuance/(repurchase) of shares, $m
  0
  10
  10
  9
  9
  8
  7
  6
  4
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  6
  12
  12
  12
  13
  13
  14
  15
  14
  14
  15
  17
  20
  22
  25
  27
  30
  32
  35
  37
  39
  42
  44
  46
  48
  50
  52
  54
  57
  59
  61
Total cash flow (excl. dividends), $m
  2
  4
  6
  8
  11
  14
  18
  23
  28
  34
  42
  54
  66
  80
  96
  113
  131
  151
  172
  194
  218
  242
  268
  295
  323
  353
  383
  415
  448
  483
  518
Retained Cash Flow (-), $m
  -3
  -10
  -10
  -9
  -9
  -10
  -13
  -17
  -20
  -25
  -29
  -34
  -39
  -43
  -48
  -53
  -58
  -63
  -68
  -72
  -77
  -81
  -86
  -90
  -94
  -98
  -102
  -107
  -111
  -115
  -120
Prev. year cash balance distribution, $m
 
  13
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  3
  5
  7
  11
  16
  23
  31
  42
  55
  71
  89
  111
  136
  164
  195
  229
  266
  307
  350
  397
  446
  498
  553
  610
  671
  734
  799
  868
  939
  1,013
Cash available for distribution, $m
 
  7
  -4
  -1
  2
  4
  5
  6
  8
  9
  13
  20
  28
  37
  48
  60
  73
  88
  104
  122
  141
  161
  183
  205
  229
  255
  281
  309
  337
  367
  398
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  7
  -4
  -1
  2
  3
  4
  4
  5
  5
  7
  9
  12
  14
  16
  17
  19
  19
  19
  19
  18
  17
  15
  13
  12
  10
  8
  7
  5
  4
  3
Current shareholders' claim on cash, %
  100
  83.0
  73.4
  67.9
  64.7
  62.7
  61.4
  60.6
  60.3
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2
  60.2

Cryoport, Inc. (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients. The Company's Cryoport Express Solution includes a cloud-based logistics operating platform, which is branded as the Cryoportal. The Company's Cryoport Express Solutions are made up of the Cryoportal software platform, Cryoport Express Shippers, Cryoport Express Smart Pak data loggers and its life sciences cold chain logistics expertise. The Cryoportal is used by the Company, its clients and its business partners to automate the entry of orders, prepare customs documentation, and to facilitate status and location monitoring of shipped orders while in transit.

FINANCIAL RATIOS  of  CryoPort (CYRX)

Valuation Ratios
P/E Ratio -28.1
Price to Sales 46.8
Price to Book 46.8
Price to Tangible Book
Price to Cash Flow -70.3
Price to Free Cash Flow -56.2
Growth Rates
Sales Growth Rate 0%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 5
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 16.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -142.9%
Ret/ On Assets - 3 Yr. Avg. -215%
Return On Total Capital -181.8%
Ret/ On T. Cap. - 3 Yr. Avg. -327.3%
Return On Equity -222.2%
Return On Equity - 3 Yr. Avg. -63%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 50%
Gross Margin - 3 Yr. Avg. 36.1%
EBITDA Margin -166.7%
EBITDA Margin - 3 Yr. Avg. -169.4%
Operating Margin -100%
Oper. Margin - 3 Yr. Avg. -133.3%
Pre-Tax Margin -166.7%
Pre-Tax Margin - 3 Yr. Avg. -169.4%
Net Profit Margin -166.7%
Net Profit Margin - 3 Yr. Avg. -169.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CYRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CYRX stock intrinsic value calculation we used $12 million for the last fiscal year's total revenue generated by CryoPort. The default revenue input number comes from 2016 income statement of CryoPort. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CYRX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CYRX is calculated based on our internal credit rating of CryoPort, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CryoPort.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CYRX stock the variable cost ratio is equal to 83.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $10 million in the base year in the intrinsic value calculation for CYRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for CryoPort.

Corporate tax rate of 27% is the nominal tax rate for CryoPort. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CYRX stock is equal to 25%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CYRX are equal to 16.4%.

Life of production assets of 10 years is the average useful life of capital assets used in CryoPort operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CYRX is equal to -9.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $18 million for CryoPort - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 23 million for CryoPort is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CryoPort at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
GEF Greif Cl A 53.23 71.81  buy
TRS TriMas 29.85 0.16  str.sell
GFN General Financ 13.85 1.49  str.sell
WAIR Wesco Aircraft 12.10 7.12  sell

COMPANY NEWS

▶ When Should You Buy Cryoport Inc (NASDAQ:CYRX)?   [Jun-27-18 08:35AM  Simply Wall St.]
▶ CryoPort, Inc. to Host Earnings Call   [12:15PM  ACCESSWIRE]
▶ ETFs with exposure to CryoPort, Inc. : December 28, 2017   [Dec-28-17 12:01PM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : December 5, 2017   [Dec-05-17 12:37PM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : November 24, 2017   [Nov-24-17 10:33AM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : November 13, 2017   [Nov-13-17 12:10PM  Capital Cube]
▶ CYRX: Record Revenue, Again. Readying To Support Immunotherapy Launches   [Nov-07-17 04:00PM  Zacks Small Cap Research]
▶ Cryoport Revenue Up 52%; Driven by BioPharma   [Nov-02-17 04:10PM  PR Newswire]
▶ Cryoport, Inc. to Host Earnings Call   [11:40AM  ACCESSWIRE]
▶ Is It Too Late To Buy Cryoport Inc (CYRX)?   [07:02AM  Simply Wall St.]
▶ ETFs with exposure to CryoPort, Inc. : November 1, 2017   [Nov-01-17 12:04PM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : October 16, 2017   [Oct-16-17 09:50AM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : October 2, 2017   [Oct-02-17 10:47AM  Capital Cube]
▶ ETFs with exposure to CryoPort, Inc. : September 19, 2017   [Sep-19-17 05:20PM  Capital Cube]
▶ CYRX: Raising Price Target on CAR-T Opportunity   [Aug-16-17 10:00AM  Zacks Small Cap Research]
▶ Cryoport Launches - Cryoport. Certified. Cool.   [Aug-15-17 08:45AM  PR Newswire]
▶ ETFs with exposure to CryoPort, Inc. : August 4, 2017   [Aug-03-17 08:10PM  Capital Cube]
▶ FDA Panel Votes To Approve CTL019, Positive Implications for CYRX   [Jul-19-17 01:30PM  Zacks Small Cap Research]
▶ CYRX: Biopharma, Clinical Trial Growth, Fuels Another Record Quarter   [May-09-17 03:40PM  Zacks Small Cap Research]
▶ Cryoport Revenue Grows by 74%, Driven by Biopharma   [May-04-17 04:10PM  PR Newswire]
▶ CYRX: Growth in Clinical Trial Customers Pushing Revenue To Record Heights   [Mar-20-17 09:00AM  Zacks Small Cap Research]
▶ Webcast-Q4 Earnings Call for CryoPort, Inc.   [Mar-07-17 11:11PM  at Company Spotlight]
▶ Cryoport Completes Warrant Tender Offer   [08:30AM  PR Newswire]
▶ Cryoport Supporting Over 100 Clinical Trials   [Oct-25-16 08:30AM  PR Newswire]
Financial statements of CYRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.